Pregledni rad
https://doi.org/10.3325/cmj.2025.66.446
Pharmacogenomics in the prediction of adverse effects of cardiovascular drugs: the PGx CardioDrug project
Tamara Božina
; Department of Medical Chemistry, Biochemistry and Clinical Chemistry, Zagreb University School of Medicine, Zagreb, Croatia
*
Lana Ganoci
; Division for Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, University Hospital Center Zagreb, Zagreb, Croatia
Livija Šimičević
; Department of Medical Chemistry, Biochemistry and Clinical Chemistry, Zagreb University School of Medicine, Zagreb, Croatia
Majda Vrkić Kirhmajer
; Department of Cardiovascular Diseases, University Hospital Center Zagreb, Zagreb, Croatia
Iva Mucalo
; Center for Applied Pharmacy, University of Zagreb Faculty of Pharmacy and Biochemistry, Zagreb, Croatia
Jure Samardžić
; Department of Cardiovascular Diseases, University Hospital Center Zagreb, Zagreb, Croatia
Jozefina Palić
; Department of Laboratory Diagnostics, University Hospital Center Zagreb, Zagreb, Croatia
Ana Marija Slišković
; Department of Cardiovascular Diseases, University Hospital Center Zagreb, Zagreb, Croatia
Vladimir Trkulja
; 3Department of Basic and Clinical Pharmacology, Zagreb University School of Medicine, Zagreb, Croatia
* Dopisni autor.
Sažetak
Although the role of pharmacogenomics (PGx) in per
sonalized pharmacotherapy has been well established,
its implementation in clinical practice lags behind. In this
article, we present an overview of important achieve
ments in the field of PGx of cardiovascular drugs (CVDs),
and identify gaps in the existing research. We also present
an outline of the PGx-CardioDrug project (ClinicalTrials.
gov: NCT05307718) focused on PGx of three major class
es of CVDs: P2Y12 antiplatelets, direct oral anticoagulants
(DOACs), and statins. The project intends to evaluate phar
macogenes, concomitant treatments, and their combina
tions as determinants of adverse drug reactions (ADRs). It
is based on a pool of around 1200 consecutive adults who
were accrued on the case-control principle defined with
respect to the CVDs and ADRs of interest (bleeding related
to antiplatelets and DOACs, skeletal muscle or liver toxic
ity related to statins, inefficiency). Possible perpetrator or
victim roles of concomitantly used drugs are assessed us
ing the Lexicomp® Clinical Decision Support System. The
assembled data provide a basis for a series of case-control
type analyses. Considering the mode of data generation
and the nature of the exposures of interest (ie, present be
fore the occurrence of the outcome), potentially observed
outcome-exposure associations are likely to be causal,
provided that confounding is reasonably controlled. The
project enables the development of methods and proce
dures that better reflect the real-life situation of patients
with comorbidities and polytherapy, and might better pre
dict the interactions of multiple drugs and genes that af
fect the frequency and severity of CVD ADRs.
Ključne riječi
Hrčak ID:
352571
URI
Datum izdavanja:
21.12.2025.
Posjeta: 0 *